Search
Afatinib
go.drugbank.com/drugs/DB08916ApprovedInvestigationalby an FDA-approved test [L2939]. … For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected
Doxorubicin
go.drugbank.com/drugs/DB00997ApprovedInvestigational[A257614] Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin … [A257709] Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and
Mepolizumab
go.drugbank.com/drugs/DB06612ApprovedInvestigationalMepolizumab was first approved by the FDA on November 4, 2015, as an add-on therapy for severe asthma and marketed under the brand name Nucala by GlaxoSmithKline. … The pathogenesis of eosinophilia is complex, but IL-5 is recognized as a key cytokine involved in the differentiation, recruitment, activation, and prolonged survival of eosinophils in peripheral tissue
Ziftomenib
go.drugbank.com/drugs/DB17171ApprovedInvestigational[A274738] This drug was approved by the FDA on November 13th, 2025, for the treatment of relapsed or refractory acute myeloid leukemia (AML) in adults with a susceptible NPM1 mutation who have no satisfactory … [L54601] Ziftomenib works by preventing the protein-protein interaction between menin and KMT2A, a complex essential for maintaining the proliferation and survival of these leukemic cells.
Synonyms: Menin-mll interaction inhibitor ko 539Sugammadex
go.drugbank.com/drugs/DB06206ApprovedInvestigationalSugammadex (brand name Bridion) is marketed by Merck Sharp and Dohme, and was approved by the United States FDA on December 15, 2015. … Sugammadex is a selective relaxant binding agent indicated for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide during surgery.
Selenium
go.drugbank.com/drugs/DB11135ApprovedInvestigationalVet approvedSelenium is a trace metal in the human body particularly important as a component of glutathione peroxidase, an important enzyme in the prevention of cellular damage by free radicals and reactive oxygen
Mixtures: ADDAMEL N, Multi Nt-OXGemtuzumab ozogamicin
go.drugbank.com/drugs/DB00056ApprovedInvestigationalOn September 1 2017, gemtuzumab ozogamicin was again approved for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia but with a lower dosing regimen and a different schedule … By binding to the CD33 antigen on tumors, the cytotoxic agent blocks the growth of cancerous cells and causes cell death.
alpha-Tocopherol succinate
go.drugbank.com/drugs/DB14001ApprovedNutraceuticalVet approvedAlpha-tocopherol is the primary form of vitamin E that is preferentially used by the human body to meet appropriate dietary requirements. … This biologic action of vitamin E consequently continues to generate ongoing interest and study in whether or not its antioxidant abilities may be used to help assist in preventing or treating a number
Mixtures: Ni-C-E-LE Plus, Formula OAncestim
go.drugbank.com/drugs/DB09103ApprovedWithdrawn[T68] It was also approved by Health Canada in 1999 but it is currently under the status of canceled post-market.[L1087] … Ancestim was developed by Amgen and sold to Biovitrium in December 2008. It was submitted to the FDA under the status of recommendation for approval with a 10 to 1 votes.
Pemetrexed
go.drugbank.com/drugs/DB00642ApprovedInvestigationalIts use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.[A253907] … Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta.